299P LUMINANCE study
Presented by Prof Dr Niels Reinmuth (Asklepios Lung Clinic – Munich-Gauting, Germany)
The CASPIAN study established durvalumab + 4 cycles of platinum-etoposide as a standard of care first line treatment patients with extensive-stage small-cell lung cancer (ES-SCLC). Building on these results, the phase IIIb LUMINANCE study assessed first line durvalumab + ≤6 cycles of EP in this setting. In this video, Prof Niels Reinmuth, thoracic oncologist at the Asklepios Lung Clinic in Gauting (Germany) discusses the updated results of the LUMINANCE study, presented during ELCC 2025.
The safety and efficacy results from the final analysis of LUMINANCE were consistent with those observed in the primary analysis and in the phase 3 CASPIAN study. The most common grade ≥3 AEs were haematological in nature and were typically associated with chemotherapy. With greater data maturity, the median OS was reported at 16.4 months, with an 18-month OS rate of 43.9%. Higher levels of MHC I or CD8 before treatment were associated with better outcomes. The same was true for lower levels of circulating tumour DNA.
As such, these results further support the use of durvalumab plus EP as 1L treatment for patients with ES-SCLC.
References:
Reinmuth N et al. ELCC 2025. Abstract 299P.
